Skip to main content
Gail Roboz, MD, Oncology, New York, NY, New York-Presbyterian Hospital

GailJRobozMD

Oncology • New York, NY

Hematologic Oncology

Associate Professor, Medicine, Weill Cornell Medical College

Request Appointment

Overview of Dr. Roboz

Dr. Gail Roboz is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and Long Island Jewish Medical Center. She received her medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 23 years. Dr. Roboz accepts several types of health insurance, listed below. She is one of 97 doctors at Long Island Jewish Medical Center and one of 369 doctors at New York-Presbyterian Hospital who specialize in Oncology. She has more than 100 publications and over 500 citings.

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1997 - 2000
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1995 - 1997
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1994 - 1995
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 1994

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1995 - 2024
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Top Doctors: New York Metro Area Castle Connolly, 2012-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Somatic Mutations Precede Acute Myeloid Leukemia Years Before Diagnosis  
    Sangmin Lee, Pinkal Desai, Gail J Roboz, Ellen K Ritchie, Nature
  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
    Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine

Abstracts/Posters

  • Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial
    Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
    Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...
    Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na¥ve (TN) AML Unfit for Intensive Chemothe... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Join now to see all

Press Mentions

  • MRD and Relapse in Patients with AML
    MRD and Relapse in Patients with AMLAugust 17th, 2022
  • Treating Older AML Patients and Managing Unique Toxicities
    Treating Older AML Patients and Managing Unique ToxicitiesJuly 20th, 2022
  • Adverse-Risk Acute Myeloid Leukemia
    Adverse-Risk Acute Myeloid LeukemiaJune 16th, 2022
  • Join now to see all

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    BCBS California CaliforniaCare HMO
    BCBS California PowerSelect HMO
    BCBS California PPO
    BCBS Illinois PPO
    Blue Shield California HMO
    Blue Shield California PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    First Health PPO
    GHI PPO
    Great West PPO
    Health Net California Large Group PPO
    Health Net HMO - Employer Group
    HIP of New York - Select PPO
    Humana ChoiceCare Network PPO
    MagnaCare PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    Pacificare HMO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
    WEA Trust Preferred Provider Plan - Trust Pref
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Gail Roboz, Dr. Gail Roboz, MD, Dr. G Roboz, Dr. Gail J Roboz